{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:41:16Z","timestamp":1793166076550,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease. Anti-citrullinated protein antibodies (ACPA) are crucial for the serological diagnosis of RA, where Epstein-Barr virus (EBV) has been suggested to be an environmental agent in triggering the onset of the disease. This study aimed to analyse antibody reactivity to citrullinated EBV nuclear antigen-2 (EBNA-2) peptides from three different EBV strains (B95-8, GD1 and AG876) using streptavidin capture enzyme-linked immunosorbent assay. One peptide, only found in a single strain (AG876), obtained a sensitivity and specificity of 77% and 95%, respectively and showed high sequence similarity to the filaggrin peptide originally used for ACPA detection. Comparison of antibody reactivity to commercial assays found that the citrullinated peptide was as effective in detecting ACPA as highly sensitive and specific commercial assays. The data presented demonstrate that the citrullinated EBNA-2 peptide indeed is recognised specifically by RA sera and that the single peptide is able to compete with assays containing multiple peptides. Furthermore, it could be hypothesized that RA may be caused by (a) specific strain(s) of EBV.<\/jats:p>","DOI":"10.1038\/s41598-018-22058-6","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T10:47:57Z","timestamp":1519210077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-2009","authenticated-orcid":false,"given":"Nicole Hartwig","family":"Trier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina Eide","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Heiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Slot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Locht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Lindegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer Tandrup","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Theander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Houen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"22058_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott, D. L., Wolfe, F. & Huizinga, T. W. Rheumatoid arthritis. Lancet 376, 1094\u20131108 (2010).","journal-title":"Lancet"},{"key":"22058_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.25036","volume":"62","author":"O Snir","year":"2010","unstructured":"Snir, O. et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 62, 44\u201352 (2010).","journal-title":"Arthritis Rheum"},{"key":"22058_CR3","first-page":"S35","volume":"26","author":"T Sokka","year":"2008","unstructured":"Sokka, T., Abelson, B. & Pincus, T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26, S35\u201361 (2008).","journal-title":"Clin Exp Rheumatol"},{"key":"22058_CR4","doi-asserted-by":"publisher","first-page":"30709","DOI":"10.1074\/jbc.271.48.30709","volume":"271","author":"E Tarcsa","year":"1996","unstructured":"Tarcsa, E. et al. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 271, 30709\u201330716 (1996).","journal-title":"J Biol Chem"},{"key":"22058_CR5","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/eji.200526000","volume":"35","author":"H Burkhardt","year":"2005","unstructured":"Burkhardt, H. et al. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 35, 1643\u20131652 (2005).","journal-title":"Eur J Immunol"},{"key":"22058_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/00365513.2016.1200133","volume":"76","author":"CE Dam","year":"2016","unstructured":"Dam, C. E., Houen, G. & Trier, N. H. The dependency on neighboring amino acids for reactivity of anti-citrullinated protein antibodies to citrullinated proteins. Scand J Clin Lab Invest 76, 417\u2013425 (2016).","journal-title":"Scand J Clin Lab Invest"},{"key":"22058_CR7","doi-asserted-by":"publisher","first-page":"R1421","DOI":"10.1186\/ar1845","volume":"7","author":"A Kinloch","year":"2005","unstructured":"Kinloch, A. et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 7, R1421\u20131429 (2005).","journal-title":"Arthritis Res Ther"},{"key":"22058_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI1316","volume":"101","author":"GA Schellekens","year":"1998","unstructured":"Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., van de Putte, L. B. & van Venrooij, W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101, 273\u2013281 (1998).","journal-title":"J Clin Invest"},{"key":"22058_CR9","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/eji.200535790","volume":"36","author":"M Sebbag","year":"2006","unstructured":"Sebbag, M. et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 36, 2250\u20132263 (2006).","journal-title":"Eur J Immunol"},{"key":"22058_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.peptides.2016.01.005","volume":"76","author":"NH Trier","year":"2016","unstructured":"Trier, N. H. et al. Application of synthetic peptides for detection of anti-citrullinated peptide antibodies. Peptides 76, 87\u201395 (2016).","journal-title":"Peptides"},{"key":"22058_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.0105-2896.2009.00853.x","volume":"233","author":"H Uysal","year":"2010","unstructured":"Uysal, H. et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 233, 9\u201333 (2010).","journal-title":"Immunol Rev"},{"key":"22058_CR12","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar1149","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar, E. R. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6, R142\u2013150 (2004).","journal-title":"Arthritis Res Ther"},{"key":"22058_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/antib6010005","volume":"6","author":"NH Trier","year":"2017","unstructured":"Trier, N. H. & Houen, G. Epitope specificity of anti-citrullinated protein antibodies. Antibodies 6, 5 (2017).","journal-title":"Antibodies"},{"key":"22058_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2010.131102","volume":"70","author":"A Ioan-Facsinay","year":"2011","unstructured":"Ioan-Facsinay, A. et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70, 188\u2013193 (2011).","journal-title":"Ann Rheum Dis"},{"key":"22058_CR15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1373\/clinchem.2007.087569","volume":"53","author":"N Bizzaro","year":"2007","unstructured":"Bizzaro, N., Tonutti, E., Tozzoli, R. & Villalta, D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 53, 1527\u20131533 (2007).","journal-title":"Clin Chem"},{"key":"22058_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2007.08.002","volume":"386","author":"L Lutteri","year":"2007","unstructured":"Lutteri, L., Malaise, M. & Chapelle, J. P. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 386, 76\u201381 (2007).","journal-title":"Clin Chim Acta"},{"key":"22058_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura, K. et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146, 797\u2013808 (2007).","journal-title":"Ann Intern Med"},{"key":"22058_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10067-007-0656-4","volume":"27","author":"M Santiago","year":"2008","unstructured":"Santiago, M. et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 27, 77\u201383 (2008).","journal-title":"Clin Rheumatol"},{"key":"22058_CR19","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/ard.2004.035089","volume":"64","author":"FA van Gaalen","year":"2005","unstructured":"van Gaalen, F. A., Visser, H. & Huizinga, T. W. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 64, 1510\u20131512 (2005).","journal-title":"Ann Rheum Dis"},{"key":"22058_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens, G. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43, 155\u2013163 (2000).","journal-title":"Arthritis Rheum"},{"key":"22058_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1373\/clinchem.2006.078063","volume":"53","author":"D Coenen","year":"2007","unstructured":"Coenen, D., Verschueren, P., Westhovens, R. & Bossuyt, X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein\/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 53, 498\u2013504 (2007).","journal-title":"Clin Chem"},{"key":"22058_CR22","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar2449","volume":"10","author":"A Svard","year":"2008","unstructured":"Svard, A., Kastbom, A., Reckner-Olsson, A. & Skogh, T. Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther 10, R75 (2008).","journal-title":"Arthritis Res Ther"},{"key":"22058_CR23","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1002\/art.22279","volume":"54","author":"KN Verpoort","year":"2006","unstructured":"Verpoort, K. N. et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54, 3799\u20133808 (2006).","journal-title":"Arthritis Rheum"},{"key":"22058_CR24","first-page":"647","volume":"33","author":"C Anzilotti","year":"2006","unstructured":"Anzilotti, C. et al. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 33, 647\u2013651 (2006).","journal-title":"J Rheumatol"},{"key":"22058_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/art.21629","volume":"54","author":"F Pratesi","year":"2006","unstructured":"Pratesi, F., Tommasi, C., Anzilotti, C., Chimenti, D. & Migliorini, P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 54, 733\u2013741 (2006).","journal-title":"Arthritis Rheum"},{"key":"22058_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2249.2011.04378.x","volume":"164","author":"F Pratesi","year":"2011","unstructured":"Pratesi, F. et al. Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clin Exp Immunol 164, 337\u2013345 (2011).","journal-title":"Clin Exp Immunol"},{"key":"22058_CR27","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/pro.2178","volume":"21","author":"NH Trier","year":"2012","unstructured":"Trier, N. H., Leth, M. L., Hansen, P. R. & Houen, G. Cross-reactivity of a human IgG(1) anticitrullinated fibrinogen monoclonal antibody to a citrullinated profilaggrin peptide. Protein Sci 21, 1929\u20131941 (2012).","journal-title":"Protein Sci"},{"key":"22058_CR28","doi-asserted-by":"publisher","first-page":"e0168542","DOI":"10.1371\/journal.pone.0168542","volume":"11","author":"NH Trier","year":"2016","unstructured":"Trier, N. H. et al. Physical Characteristics of a Citrullinated Pro-Filaggrin Epitope Recognized by Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Sera. PLoS One 11, e0168542 (2016).","journal-title":"PLoS One"},{"key":"22058_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1084\/jem.20081862","volume":"206","author":"H Uysal","year":"2009","unstructured":"Uysal, H. et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 206, 449\u2013462 (2009).","journal-title":"J Exp Med"},{"key":"22058_CR30","doi-asserted-by":"publisher","first-page":"e0144707","DOI":"10.1371\/journal.pone.0144707","volume":"10","author":"NH Trier","year":"2015","unstructured":"Trier, N. H., Dam, C. E., Olsen, D. T., Hansen, P. R. & Houen, G. Contribution of Peptide Backbone to Anti-Citrullinated Peptide Antibody Reactivity. PLoS One 10, e0144707 (2015).","journal-title":"PLoS One"},{"key":"22058_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1021\/bc400073z","volume":"24","author":"F Babos","year":"2013","unstructured":"Babos, F. et al. Role of N- or C-terminal biotinylation in autoantibody recognition of citrullin containing filaggrin epitope peptides in rheumatoid arthritis. Bioconjug Chem 24, 817\u2013827 (2013).","journal-title":"Bioconjug Chem"},{"key":"22058_CR32","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3899\/jrheum.131375","volume":"41","author":"J Payet","year":"2014","unstructured":"Payet, J. et al. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J Rheumatol 41, 2395\u20132402 (2014).","journal-title":"J Rheumatol"},{"key":"22058_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/ar2903","volume":"12","author":"GJ Pruijn","year":"2010","unstructured":"Pruijn, G. J., Wiik, A. & van Venrooij, W. J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 12, 203 (2010).","journal-title":"Arthritis Res Ther"},{"key":"22058_CR34","first-page":"815038","volume":"2011","author":"P Taylor","year":"2011","unstructured":"Taylor, P., Gartemann, J., Hsieh, J. & Creeden, J. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011, 815038 (2011).","journal-title":"Autoimmune Dis"},{"key":"22058_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12026-013-8425-8","volume":"56","author":"Z Szekanecz","year":"2013","unstructured":"Szekanecz, Z. et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res 56, 439\u2013443 (2013).","journal-title":"Immunol Res"},{"key":"22058_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jmv.24633","volume":"89","author":"M Neves","year":"2017","unstructured":"Neves, M., Marinho-Dias, J., Ribeiro, J. & Sousa, H. Epstein-Barr virus strains and variations: Geographic or disease-specific variants? J Med Virol 89, 373\u2013387 (2017).","journal-title":"J Med Virol"},{"key":"22058_CR37","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1128\/JVI.03614-14","volume":"89","author":"AL Palser","year":"2015","unstructured":"Palser, A. L. et al. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. J Virol 89, 5222\u20135237 (2015).","journal-title":"J Virol"},{"key":"22058_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jneuroim.2011.12.020","volume":"243","author":"NH Trier","year":"2012","unstructured":"Trier, N. H., Hansen, P. R., Vedeler, C. A., Somnier, F. E. & Houen, G. Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases\/small cell lung cancer. J Neuroimmunol 243, 25\u201333 (2012).","journal-title":"J Neuroimmunol"},{"key":"22058_CR39","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum"},{"key":"22058_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315\u2013324 (1988).","journal-title":"Arthritis Rheum"},{"key":"22058_CR41","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25, 1271\u20131277 (1982).","journal-title":"Arthritis Rheum"},{"key":"22058_CR42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali, C. et al. Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61, 554\u2013558 (2002).","journal-title":"Ann Rheum Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22058-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:53:44Z","timestamp":1671591224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22058-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["22058"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-22058-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3684"}}